FDA Accepts FYB206 Keytruda® Biosimilar for Review

Formycon AG and Zydus Lifesciences Limited have announced that the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda®. This development is a significant milestone, as it marks one of the first public announcements of such an acceptance. The application was submitted in the third quarter of 2026.

FYB206 was developed without a comparative Phase III efficacy trial, in line with an FDA-agreed pathway established in early 2025. This approach has expedited the development and reduced investment costs while maintaining rigorous scientific standards. Formycon benefits from a milestone payment under their licensing agreement with Zydus, which retains exclusive commercialization rights in the U.S. and Canada.

The FDA review is expected to be completed within 12 months, targeting a decision by the third quarter of 2027. Additionally, the regulatory dossier for FYB206 has been filed with Health Canada. As demand for affordable oncology treatments rises, FYB206 aims to expand patient access in the North American market.